KALV — KalVista Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1348911 ·
Last close
$26.81
Market Cap
$1.43B
52W High
$26.85
52W Low
$15.09
ADV30
5,624,124
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 40,863,000 | 37,773,000 | -23,442,000 | -23,487,000 | 328,917,000 | 213,768,000 | 348,569,000 |
| Sep 2025 | 13,692,000 | 12,460,000 | -46,050,000 | -49,482,000 | 339,931,000 | 243,497,000 | 322,932,000 |
| Jul 2025 | 1,426,000 | 836,000 | -59,009,000 | -60,096,000 | 215,505,000 | 124,304,000 | 174,715,000 |
| Apr 2025 | 0 | — | -50,016,000 | -52,226,000 | 250,770,000 | 131,615,000 | 155,379,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-167,189,000
Investing CF
$75,123,000
Financing CF
$179,937,000
CapEx
$-1,281,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-739,098,000
Inventory
$458,000
Receivables
$7,122,000
ST Investments
$65,661,000
EBIT TTM
$-188,543,000
Pretax Income TTM
$-202,607,000
Interest Exp TTM
$14,064,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$114,480,000
EBITDA
$-138,447,008
Free Cash Flow
—
Enterprise Value
$1,425,605,376
Total Cash
$285,030,016
Total Debt
$284,312,000
Shares Out
53,240,888
Trailing EPS
$-3.94
Book Value
$-0.05
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | 335,375,000 | 338,086,000 | — | — |
| Apr 2025 | 0 | -182,981,000 | -183,444,000 | 250,770,000 | 155,379,000 | — | -152,907,000 |
| Apr 2024 | 0 | -131,993,000 | -126,644,000 | 235,404,000 | 28,822,000 | — | -89,231,000 |
| Apr 2023 | 0 | -95,086,000 | -92,907,000 | 183,202,000 | 22,177,000 | — | -75,261,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | $1.44B | $29.46 | — |
| BCAX | Bicara Therapeutics Inc. | $1.44B | $21.98 | — |
| SEPN | Septerna, Inc. | $1.38B | $30.65 | — |
| PRGO | PERRIGO Co plc | $1.49B | $10.80 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.51B | $8.12 | — |
News headlines (Yahoo Finance, 1h cache)
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains
2026-05-10 00:24 · Yahoo
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
2026-04-30 11:50 · Yahoo
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
2026-04-30 09:09 · Yahoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
2026-04-29 22:07 · Yahoo
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
2026-04-29 20:03 · Yahoo
Sector Update: Health Care Stocks Fall Late Afternoon
2026-04-29 19:47 · Yahoo
Top Midday Stories: Visa Shares Rise After Strong Q2 Earnings, $20 Billion Buyback Program; Robinhood Misses Q1 EPS, Revenue Targets
2026-04-29 15:40 · Yahoo
Top Premarket Gainers
2026-04-29 12:03 · Yahoo
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
2026-04-29 11:42 · Yahoo
Chiesi to buy KalVista in $1.9B deal for rare disease drug
2026-04-29 11:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.